These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 30449777)

  • 61. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 62. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
    Ratra A; Dasanu CA
    J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient.
    Cancela-Díez B; Gómez-De Rueda F; Antolinos Pérez MJ; Jiménez-Morales A; López-Hidalgo JL
    J Oncol Pharm Pract; 2020 Jan; 26(1):252-255. PubMed ID: 31382863
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
    Xu W; Moor RJ; Walpole ET; Atkinson VG
    Melanoma Res; 2019 Jun; 29(3):333-337. PubMed ID: 30730328
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
    Tabchi S; Weng X; Blais N
    Lung Cancer; 2016 Sep; 99():123-6. PubMed ID: 27565926
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.
    Pluvy J; Brosseau S; Stelianides S; Danel C; Nguenang M; Khalil A; Crestani B; Zalcman G; Gounant V
    BMC Pulm Med; 2019 Jan; 19(1):12. PubMed ID: 30634951
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
    Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
    Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
    Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
    JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
    [No Abstract]   [Full Text] [Related]  

  • 70. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
    Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
    Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
    [No Abstract]   [Full Text] [Related]  

  • 71. Immune checkpoint therapy in proteinuric kidney disease.
    Takenaka T; Kawai Y; Amano T
    Eur J Cancer; 2018 May; 95():120-122. PubMed ID: 29530540
    [No Abstract]   [Full Text] [Related]  

  • 72. Immunotherapy-induced severe neutropenia with neurotoxicity: A case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma.
    Patel R; Pai L
    J Oncol Pharm Pract; 2020 Apr; 26(3):730-734. PubMed ID: 31315551
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    Yano Y; Kurebe H; Edahiro R; Hosono Y; Nakatsubo S; Nishida K; Sawa N; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    PLoS One; 2018; 13(8):e0203070. PubMed ID: 30153300
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report.
    Kubo T; Hino A; Fukushima K; Shimomura Y; Kurashige M; Kusakabe S; Nagate Y; Fujita J; Yokota T; Kato H; Shibayama H; Tanemura A; Hosen N
    Int J Hematol; 2022 Aug; 116(2):302-306. PubMed ID: 35201591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
    Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
    Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
    [No Abstract]   [Full Text] [Related]  

  • 77. Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report.
    Inadomi K; Kumagai H; Arita S; Tsuruta N; Takayoshi K; Mishima K; Ota SI; Tanaka M; Okumura Y; Sagara K; Nio K; Nakano M; Uchi H; Yamamoto H; Ariyama H; Kusaba H; Niiro H; Oda Y; Akashi K; Baba E
    Medicine (Baltimore); 2016 Jul; 95(29):e4283. PubMed ID: 27442668
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
    Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
    Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    Hsu JC; Lin JY; Hsu MY; Lin PC
    PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Severe infusion reaction due to nivolumab: A case report.
    Kumari S; Yun J; Soares JR; Ding PN
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1246. PubMed ID: 32671983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.